Introduction
The ErbB family of receptor tyrosine kinases induce growth, differentiation and survival signaling in a variety of cell types by conveying signals upon binding of different ligands [reviewed in refs. [1] [2] [3] . The ErbB family consists of four closely related members: epidermal growth factor (EGF) receptor (EGFR, also known as ErbB1 or HER1), ErbB2 (HER2/Neu), ErbB3 (HER3) and ErbB4 (HER4). Signal transduction by these receptor tyrosine kinases depends on their dimerization (4, 5) . Despite their overall similar structure, ErbB proteins differ in their properties with respect to ligand-binding and kinase activity. EGFR and ErbB4 both bind ligands and form homoand/or heterodimers, whereas ErbB2 is an orphan receptor incapable of binding ligand (6, 7) . While non-liganded receptors normally exist in a folded conformation preventing dimerization, ErbB2 has a constitutively extended conformation, making it constantly available for interaction with other ErbB proteins (8) . ErbB3 can bind several ligands but was for a long time considered kinase dead (9) (10) (11) . It was recently reported that ErbB3 in fact possesses weak tyrosine kinase activity but that efficient phosphorylation depends on heterodimerization (12, 13) . ErbB3 is also considered unable to form homodimers (14) . The ErbB2-ErbB3 signaling complex is potent in mediating anti-apoptotic signaling (15) , and recent studies have reported a critical role for ErbB3 in mediating EGFR-dependent proliferative signaling in pancreatic cancers (16) . Even though ErbB3 has little oncogenic potential in its own capacity, when trans-phosphorylated, it efficiently induces activation of phosphoinositide 3-kinase, since it has six binding sites for the p85 subunit (17) (18) (19) . These characteristics make ErbB3 an important player in tumor biology and an interesting target for anticancer therapy [reviewed in refs. 8, [20] [21] [22] .
Receptor downregulation is essential to fine-tune signaling [reviewed in ref . 23] . While EGFR is known to undergo EGF-induced endocytosis and lysosomal degradation [reviewed in refs. 8, 24, 25] , several lines of evidence have suggested that other ErbB proteins are endocytosed inefficiently (26) (27) (28) . ErbB2, -3 and -4 have, in contrast to EGFR, been reported not to interact with the clathrin adaptor protein complex-2 and therefore to be inefficiently internalized (26) . The full explanation for ErbB2's endocytosis impairment is still unclear but could result from stabilization upon interaction of ErbB2 with heat shock protein Hsp90 (29) . Furthermore, it appears that unlike EGFR homodimers, ligandactivated EGFR-ErbB2 heterodimers are unable to induce formation of clathrin-coated pits and/or to translocate into clathrin-coated pits (28, 30) . To what extent ErbB3 is endocytosed and whether heterodimerization and transactivation are required for internalization of ErbB3 has also been unclear. ErbB3 was first suggested to be endocytosis impaired, based on a study demonstrating that the chimeric receptor consisting of the EGFR extracellular domain and the ErbB3 intracellular domain failed to efficiently internalize 125 I-EGF (26) . It was later reported that ErbB3 had a very low rate of ligand-dependent internalization (31) , whereas it was in other studies proposed that ErbB3 was internalized and efficiently recycled (27) . It has also by several authors been reported that ErbB3 has a relatively short half-life (around 2.5-3.5 h) (27, 32, 33) . The ErbB3 ligand heregulin (HRG) exists in a number of isoforms, which all share an EGF-like domain but differ with respect to the N-terminal domain (32) . A short recombinant HRG-b1, containing the EGF-like domain only (herein referred to as HRG-b1), was demonstrated to have no effect on the turnover of surface-localized ErbB3. However, downregulation of ErbB3 was enhanced in MCF-7 breast cancer cells by incubation with a recombinant HRG-b1, containing the immunoglobulin (Ig)-like domain, herein referred to as HRG-b1 extracellular domain (HRG-b1 ECD). This could be due to increased ability of HRG-b1 ECD to disrupt higher order oligomers of ErbB3 (32) . The ubiquitin ligase neuregulin receptor degradation protein-1 (Nrdp1) has further been reported to be involved in the constitutive ubiquitination and proteasomal degradation of ErbB3 (34, 35) . Increased stability of Nrdp1 has in turn been suggested to correlate with increased levels of the deubiquitinating protein Ubiquitin C-terminal hydrolase 8 (USP8, also called UBPY) (36) . Interestingly, USP8 appears to be upregulated by binding of HRG-b1 to ErbB3. The half-life of ErbB3 was reported to be 2.5 h in the absence of HRG-b1 but 0.5 h in the presence of HRG-b1 (33) . It should be noted that some cancer cells, in addition to having increased levels of ErbB proteins, have decreased levels of Nrdp1, thereby making the ubiquitin-dependent control of ErbB3 levels inefficient (37) .
Endocytosis of signaling receptors is important in counteraction of carcinogenesis. This is because upon internalization, the receptor cannot longer bind growth factors localized extracellularly. Furthermore, proteins in early endosomes will either be recycled to the plasma membrane or sorted to late endosomes/lysosomes, where degradation of both ErbB proteins and their bound ligands will occur. The extent of ErbB3 endocytosis and the potential mechanisms involved in ErbB3 internalization are still unclear and debated. We have in the current study investigated characteristics of ErbB3 endocytosis. We now report that like in case of ErbB2, dimerization of ErbB3 with EGFR has an inhibitory effect on endocytosis of EGF. However, the inhibitory effect on EGFR downregulation is less pronounced than in case of EGFR-ErbB2 dimers. We also demonstrate that ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner but independently of its tyrosine phosphorylation.
Materials and methods

Materials
Human recombinant EGF was from Bachem AG (Bubendorf, Switzerland), HRG-b1 ECD was from R&D Systems (Minneapolis, MN) and TO-PRO-3 iodide was from Life Technologies (Carlsbad, CA). Other chemicals were from Sigma Chemicals Co. (St Louis, MO) unless otherwise noted.
Cell culture and treatment HeLa cells, MCF-7 cells and SK-BR-3 cells were grown in Dulbecco's modified Eagle's medium with L-glutamine (2 mM). Porcine aortic endothelial (PAE) cell lines were grown in Ham's F-12 medium with L-glutamine (2 mM). Media were from the Lonza Group Ltd (Basel, Switzerland). For all cells, 0.5 Â penicillinstreptomycin (Lonza Group Ltd) and 10% fetal bovine serum were routinely used, whereas for SK-BR-3 cells, 15% fetal bovine serum was used. Stably transfected PAE cells expressing EGFR only (PAE.B2, here referred to as PAE.EGFR) were from Alexander Sorkin (University of Pittsburgh, Pittsburgh, PA). PAE.EGFR.ErbB2 and PAE.EGFR.ErbB3 cells were described previously (28, 38) . PAE.ErbB3 cells were established by stable transfection of PAE cells (obtained from Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden), using the plasmid pcDNA3.1 Hygro(þ) ErbB3 (38) and standard single cell cloning procedures (39) . The transfection reagent FuGENE 6 (Roche Diagnostics, Indianapolis, IN) was used in accordance with the manufacturer's recommendations. Geniticin (G418) (400 lg/ml), zeocin (30 lg/ml) and hygromycin (60 lg/ml) (all from Life Technologies) were added to the media used for the stably transfected PAE cells to select for clones stably expressing EGFR, ErbB2 and ErbB3, respectively. For receptor expression levels in HeLa, SK-BR-3 and PAE cells, see Supplementary Figure S1 , available at Carcinogenesis Online. For receptor activation experiments, 10 nM EGF (60 ng/ml), 10 nM HRG-b1 (80 ng/ml) or 10 nM HRG-b1 ECD (269 ng/ml) was added to cells in minimal essential medium (MEM) without bicarbonate (Life Technologies) in the presence of 0.1% bovine serum albumin. In experiments investigating downregulation from the plasma membrane and degradation of EGFR or ErbB3, 25 lg/ml cycloheximide (CHX) and 10 nM EGF, HRG-b1 or HRG-b1 ECD was added. For activation of c-Met, 1.25 nM hepatocyte growth factor (100 ng/ml) was used and to inhibit the c-Met kinase activity, cells were preincubated with 2 lM SU11274 overnight and then serum starved in MEM with 2 lM SU11274 for 15 min before incubation with hepatocyte growth factor in the presence of SU11274. For inhibition of ErbB3 phosphorylation, 5 lM AG1478 (Life Technologies) was used, including 2 h serum starvation and preincubation with MEM containing AG1478.
Plasmids and small interfering RNAs
For knockdown of clathrin heavy chain (CHC), the target sequence was GCAAUGAGCUGUUUGAAGA (40) . Control cells were transfected with either Silencer Negative Control #1 or with small interfering RNA (siRNA) to green fluorescent protein (target sequence: GCACAAGCUCCACUGCAA-CUACA), as indicated in figure legends and as described previously (41) . All siRNA duplexes were synthesized and annealed by Life Technologies. For transient expression of ErbB3, the pcDNA3.1 Hygro(þ) ErbB3 plasmid was used (38) . 
Transfection of cells
Antibodies
Mouse anti-ErbB3 and mouse anti-EGFR antibodies were from Lab Vision (Fremont, CA). Sheep anti-EGFR antibody was from Fitzgerald Industries International (Concord, MA). Rabbit anti-ErbB3, goat anti-Akt, rabbit antiErk and rabbit anti-Numb antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-b-actin and rabbit anti-b-tubulin antibodies were from Abcam (Cambridge, UK). Rabbit anti-p-ErbB3 (pY1289), rabbit antip-Erk and rabbit anti-p-Akt antibodies were from Cell Signaling Technology (Danvers, MA). Mouse anti-p-EGFR (pY1173) and rabbit anti-early endosome antigen 1 (EEA1) antibodies were from Millipore (Billerica, MA). Alexa Fluor 488-conjugated goat anti-mouse IgG, Alexa Fluor 647-conjugated donkey anti-rabbit IgG, rabbit anti-p-Met (pY1234/1235) and mouse anti-transferrin receptor antibodies were from Life Technologies. Rhodamine-Red-Xconjugated donkey anti-rabbit IgG, phycoerythrin-conjugated goat anti-mouse IgG and peroxidase-conjugated donkey anti-rabbit, anti-sheep, anti-goat and anti-mouse IgG antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). Mouse anti-CHC antibody was from BD Biosciences (Erembodegem, Belgium).
Western blotting
Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting as described (42), and proteins were detected using SuperSignal West Dura Extended Duration Substrate from Pierce (Thermo Fisher Scientific, Rockford, IL). Proteins were visualized using the KODAK Image Station 4000R from Carestream Health (Rochester, NY). Quantifications were performed using KODAK Molecular Imaging software, version 4.0. I-EGF in combination with 10 nM HRG-b1 or HRG-b1 ECD for the times indicated. Cells were lysed in 1% sodium dodecyl sulfate in phosphate-buffered saline for 10 min on ice, and the radioactivity in the fractions containing cell surface-bound and internalized 125 I-EGF was measured in a c-counter (1470 Wallac WIZARD, PerkinElmer). Statistical significance was tested using the two-tailed Student's t-test.
Flow cytometry analysis Cells were incubated as described in figure legends before being trypsinized and fixed in 4% paraformaldehyde (Riedel-de Haën, Seelze, Germany) in Sorensen's phosphate buffer. Flow cytometry analysis was performed as described previously (43) , using mouse anti-ErbB3, mouse anti-EGFR and phycoerythrin-conjugated goat anti-mouse IgG antibodies. The samples were analyzed using a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA). A minimum of 10 000 cells were analyzed for each sample. Unstained cells, incubated with the secondary antibody only, were included in the analysis to show background fluorescence. Statistical significance was tested using the two-tailed Student's t-test.
Immunocytochemistry and confocal microscopy Cells were grown in 6 cm culture dishes and incubated as described in figure legends before being fixed in 4% paraformaldehyde and immunostained as described (28) . The cells were examined by confocal microscopy analysis (Leica TCS SP; Leica Microsystems AG, Wetzlar, Germany and Olympus FluoView FV1000; Olympus Corporation, Tokyo, Japan), and pictures were processed using Adobe Photoshop CS4.
Results
ErbB3 was endocytosed in the absence of added ligand, independently of other ErbB proteins and independently of its phosphorylation Since downregulation of ErbB3 from the plasma membrane is poorly understood, we investigated the efficiency by which ErbB3 was downregulated in PAE.EGFR.ErbB3 cells. In non-stimulated cells immunolabeled with antibodies to ErbB3 or EGFR, ErbB3 was found both at the plasma membrane and in intracellular vesicles ( Figure 1A , upper panels). These vesicles were both EEA1 positive and EEA1 negative. In contrast, non-liganded EGFR appeared mostly at the cell surface, not colocalizing with EEA1 ( Figure 1A , lower panels).
To confirm that ErbB3 was internalized from the plasma membrane, PAE.EGFR.ErbB3 cells were incubated on ice with an antibody that recognized the extracellular part of ErbB3 (44) . The cells were then washed to remove unbound antibody and either left on ice or chased at 37°C for 15 min before fixation. While cells incubated on ice displayed clear plasma membrane staining for the anti-ErbB3 antibody (Supplementary Figure S2A , available at Carcinogenesis Online), in cells incubated at 37°C, anti-ErbB3 antibody was also observed in EEA1 positive endosomes (Supplementary Figure S2B and D, available at Carcinogenesis Online). To make sure that endocytosis of ErbB3 was not induced by the antibody, the cells were incubated with or without anti-ErbB3 antibody for 30 min on ice and subsequently washed and chased in MEM for 30 min at 37°C. Upon fixation, the cells were stained with the same antibody before the amount of anti-ErbB3 antibody at the plasma membrane was analyzed by flow cytometry. The cells that had been preincubated with antibody showed no reduction in ErbB3 plasma membrane level (Supplementary Figure S2E and F, available at Carcinogenesis Online). Instead, the level of ErbB3 at the plasma membrane was slightly increased. This increase could potentially be explained by longer incubation with the antibody allowing increased binding (prefixation and postfixation incubation) and/or by increased antibody affinity for native (prefixation) ErbB3 compared with ErbB3 exposed to fixatives.
To directly compare the rate of downregulation of EGFR and ErbB3 from the plasma membrane, PAE.EGFR.ErbB3 cells were incubated with or without CHX for 5 h at 37°C, and the surface levels of EGFR and ErbB3 were then analyzed by flow cytometry. The rate 
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of ErbB3 downregulation from the cell surface ( Figure 1B ) was significantly higher than for the EGFR ( Figure 1C ). While .50% of ErbB3 was downregulated from the plasma membrane upon 5 h incubation, the level of EGFR was only reduced by 20% ( Figure 1D ).
We additionally examined endocytosis of ErbB3 in human cells. Since endogenous ErbB3 was not detectable in HeLa cells (Supplementary Figure S1A , available at Carcinogenesis Online), we transiently transfected HeLa cells with an ErbB3-encoding plasmid. Upon incubation with anti-ErbB3 antibody and chase for 30 min at 37°C, anti-ErbB3 antibodies localized intracellularly in both SK-BR-3 cells (Supplementary Figure S3, (Figures 2A and 3B) .
ErbB3 has been found to dimerize with and be activated by c-Met (45) (46) (47) , and PAE cells endogenously express c-Met (48) Figure 2B ).
We observed a small constitutive phosphorylation of ErbB3 in PAE.ErbB3 cells, accompanied by constitutive activation of Erk and Akt ( Figure 3A) . As also demonstrated in Figure 3A , phosphorylation of ErbB3, Erk and Akt increased upon incubation with HRG-b1. The constitutive, as well as the HRG-b1-induced signaling, was not affected by c-Met kinase inhibition (data not shown). It has been proposed that c-Src can phosphorylate ErbB3 and that this phosphorylation can be reduced using an inhibitor of c-Src kinase activity (50, 51) . However, when we used the c-Src kinase specific inhibitor SU6656 (52), we did not observe any effect on the ErbB3 phosphorylation (data not shown). The EGFR kinase inhibitor, AG1478, has been reported to inhibit HRG-b1-induced phosphorylation of ErbB2 and ErbB3, in addition to inhibiting the EGFR (53) . Consistently, when we incubated PAE.ErbB3 cells with AG1478, both the constitutive and the HRG-b1-induced phosphorylation of ErbB3, Erk and Akt were efficiently blocked ( Figure 3A ). This could either suggest that ErbB3 to some extent forms homodimers and that AG1478 is not fully EGFR specific or that there are small amounts of AG1478-inhibitable non-defined kinase activity in PAE cells. Internalization of ErbB3 was, however, not inhibited upon incubation with AG1478 ( Figure 3B ). Also in MCF-7 cells, did AG1478 efficiently block HRGb1-induced signaling (Supplementary Figure S4A, Figure S4B , available at Carcinogenesis Online). These data support the notion that ErbB3 is internalized in the absence (A) PAE.ErbB3 cells were preincubated with or without the EGFR kinase inhibitor AG1478 (5 lM) for 2 h. The cells were then incubated (±kinase inhibitor) with or without 10 nM HRG-b1 for 3 min at 37°C. The cells were lysed and subjected to western blotting using antibodies to phosphorylated and total ErbB3, Akt and Erk. Antibody to transferrin receptor (a-TfR) was used as loading control. (B) PAE.ErbB3 cells were preincubated with or without AG1478 (5 lM) for 2 h. The cells were then incubated with mouse anti-ErbB3 antibody (in MEM with 0.1% bovine serum albumin ±kinase inhibitor) for 30 min on ice before washing in ice-cold phosphate-buffered saline and chasing in MEM (±kinase inhibitor) for 15 min at 37°C before fixation. After permeabilization, localization of anti-ErbB3 antibody was detected with Alexa Fluor 488-conjugated anti-mouse antibody. Early endosomes were localized with rabbit anti-EEA1 antibody followed by Alexa Fluor 647-conjugated anti-rabbit antibody. The cells were analyzed by confocal microscopy. Scale bar, 10 lm. The figure shows one representative experiment of three.
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of added ligand and that endocytosis does not depend on ErbB3 phosphorylation.
Endocytosis of ErbB3 was clathrin dependent
To study by which endocytic pathway ErbB3 is internalized, we transfected PAE.EGFR.ErbB3 cells with siRNA to CHC. As demonstrated, the level of CHC was strongly reduced, whereas the level of ErbB3 remained almost unchanged ( Figure 4A ). Since EGFR is mainly endocytosed in a clathrin-dependent manner (40, 54, 55) , EGF-induced downregulation of EGFR from the plasma membrane was used as a positive control. As expected, the EGFR level was also unchanged, and ligand-induced downregulation of EGFR was strongly inhibited in clathrin-depleted cells (Supplementary Figure S5A- C, available at Carcinogenesis Online). We then investigated the internalization of anti-ErbB3 antibodies and found that while cells transfected with control siRNA exhibited vesicular anti-ErbB3 staining ( Figure 4B , left panel), cells depleted of clathrin displayed a strong plasma membrane staining ( Figure 4B, right panel) . The inhibition of ErbB3 endocytosis in cells transfected with siRNA to CHC was quantified manually. Data showed that depletion of CHC efficiently inhibited endocytosis of ErbB3, since ,10% of the cells showed endosomal labeling for antiErbB3 ( Figure 4C ). Also, flow cytometry analysis confirmed that downregulation of ErbB3 from the plasma membrane in cells where CHC had been depleted was significantly inhibited ( Figure 4D and E). CHC knockdown strongly reduced ErbB3 internalization also in MCF-7 cells (Supplementary Figure S5D and E, available at Carcinogenesis Online). We thus conclude that the observed internalization of ErbB3 is clathrin dependent.
ErbB3 was activated upon incubation with ligand but was degraded independently of added ligand
To investigate whether ErbB3 and EGFR formed functional heterodimers in PAE cells, we investigated receptor phosphorylation in PAE.EGFR.ErbB3 cells. The cells were incubated with or without EGF, HRG-b1, HRG-b1 ECD or combinations of each HRG and EGF. Cell lysates were then subjected to western blotting using phosphotyrosine-specific antibodies. Although, when compared with PAE.ErbB3 cells, PAE.EGFR.ErbB3 cells express less ErbB3 (see Supplementary Figure S1 , available at Carcinogenesis Online), HRG-b1-and HRG-b1 ECD-induced phosphorylation of ErbB3 were most pronounced in PAE.EGFR.ErbB3 cells ( Figure 5A compare with Figure 3A ). This strongly suggests that HRG can induce formation of EGFR-ErbB3 heterodimeres followed by EGFR-mediated transphosphorylation of ErbB3. Phosphorylation of ErbB3 was, however, not increased upon incubation with EGF. Activation of EGFR was clearly induced by addition of EGF but not by HRG-b1 or HRG-b1 ECD ( Figure 5A ). This is consistent with the notion that while ErbB3 can transactivate and be trans-phosphorylated by the EGFR, the EGFR cannot be trans-phosphorylated by ErbB3, which has marginal kinase activity (13) . In the samples where EGF was added in 
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combination with either HRG-b1 or HRG-b1 ECD, there was a reduced phosphorylation of ErbB3 compared with upon incubation with each HRG variant alone. This could possibly be explained by EGFinduced formation of EGFR homodimers and consequently reduced amounts of EGFR available for ErbB3 interaction. The formation of functional dimers was confirmed by the observed activation of downstream targets ( Figure 5A ). Erk was activated upon incubation with either ligand but appeared most intensely phosphorylated in the presence of EGF. Akt phosphorylation, on the other hand, was strongest upon incubation with the HRGs, consistent with the finding that ErbB3 signals mainly through the phosphoinositide 3-kinase/Akt pathway (16) .
HRG-b1 was previously demonstrated to have no effect on the turnover of surface-localized ErbB3, while downregulation of ErbB3 was enhanced by HRG-b1 ECD in MCF-7 breast cancer cells, and this could be due to better ability of HRG-b1 ECD to disrupt higher order oligomers of ErbB3 (32) . To investigate whether the ligands had similar effect in PAE cells, we examined degradation of total ErbB3 in the presence of different ligands. PAE.EGFR.ErbB3 cells were incubated without ligand, with EGF, with HRG-b1 or with HRG-b1 ECD for different times in the presence of CHX. Then, the amount of residual ErbB3 and EGFR was studied by western blotting. While degradation of EGFR was clearly induced by EGF, ErbB3 was found to be efficiently degraded even in the absence of ligand ( Figure 5B Figure 5C ).
HRG-b1 and HRG-b1 ECD both reduced EGF-induced endocytosis of the EGFR
We have previously demonstrated that overexpression of ErbB2 inhibited EGF-induced endocytosis of the EGFR (28) . We therefore wanted to study whether overexpression of ErbB3 had a similar effect on endocytosis of the EGFR. The rate of 125 I-EGF internalization in PAE.EGFR cells, in PAE.EGFR.ErbB2 cells and in PAE.EG-FR.ErbB3 cells was compared ( Figure 6A ). While the rate of endocytosis of 125 I-EGF was significantly inhibited in PAE.EGFR.ErbB2 cells, no significant inhibition was observed in PAE.EGFR.ErbB3 cells incubated with EGF only when compared with PAE.EGFR cells. To study the efficiency of EGFR downregulation from the cell surface, the same cell lines were incubated for 5 h in the presence of CHX, with or without EGF. The level of EGFR at the plasma membrane was investigated by flow cytometry analysis ( Figure 6B ). Consistent with data using 125 I-EGF, we found that downregulation of cell surfacelocalized EGFR was significantly inhibited in PAE.EGFR.ErbB2 cells but not in PAE.EGFR.ErbB3 cells. Altogether, our data thus argue that in contrast to ErbB2, expression of ErbB3 as such does not negatively impact on downregulation of the EGFR. However, when PAE.EG-FR.ErbB3 cells were incubated with EGF in combination with either HRG-b1 or HRG-b1 ECD, the rate of EGF internalization was significantly reduced by $25% (Figure 6C) . A similar result was observed in MCF-7 cells (Supplementary Figure S6A , available at Carcinogenesis Online). This is consistent with ligand-induced heterodimerization upon incubation with HRG-b1 and EGF, but not with EGF alone, and supports the idea that EGFR-ErbB3 heterodimers are internalized less efficiently than are EGFR homodimers. It should be noted that HRG-b1 ECD did not affect the internalization of EGF in cells not expressing ErbB3 (Supplementary Figure S6B , available at Carcinogenesis Online).
Discussion
We have previously demonstrated that ErbB2 negatively impacts on the ligand-induced downregulation of EGFR, presumably by tethering EGFR to the endocytosis-resistant ErbB2 (28, 56) . In the current study, we show that ErbB3, upon coexpression with EGFR in PAE cells, did not affect EGF-induced downregulation of EGFR from the plasma membrane. Although ErbB3 without bound ligand probably does not form heterodimers with the EGFR to same extent as does ErbB2, the data show that expression of ErbB3 as such does not have a negative impact on EGF-induced EGFR endocytosis. Ligands to ErbB3 have previously been shown to induce EGFR-ErbB3 heterodimerization (57) (58) (59) (60) . In line with this, we observed increased HRG-b1-induced phosphorylation of ErbB3 in PAE.EGFR.ErbB3 cells compared with in PAE.ErbB3 cells, supporting the formation of functional EGFR-ErbB3 heterodimers. Also, when cells were incubated with EGF and HRG-b1 or HRG-b1 ECD, expression of ErbB3 did in fact reduce endocytosis of EGF, suggesting that ligand-induced EGFR-ErbB3 heterodimerization inhibits EGFR endocytosis. The results from the activation and internalization experiments may seem contradictory. We observed that incubation with HRG-b1 and EGF together caused reduced phosphorylation of ErbB3 when compared with incubation with HRGb1 only and suggest that this is due to EGF-induced EGFR homodimerization and consequently reduced EGFR-ErbB3 heterodimerization. At the same time, we observed decreased internalization of EGF when HRG-b1 was added along with EGF and explained this with ligandinduced EGFR-ErbB3 heterodimerization. These two explanations are, however, not necessarily contradictory based on the following scenario.
When HRG-b1 is added alone, EGFR-ErbB3 heterodimers will be formed and ErbB3 will be strongly trans-phosphorylated by the EGFR. When EGF is added alone, only EGFR homodimers will be formed, as shown by the lack of ErbB3 phosphorylation. This is in line with previous data showing EGF-induced phosphorylation of ErbB3 only in cells with high expression of ErbB3 (16), indicating inefficient EGF-induced EGFR-ErbB3 heterodimerization. When HRG-b1 and EGF are added together, the two ligands will, however, compete with respect to formation of different dimers. EGF will preferentially induce EGFR homodimers and reduce the amount of EGFR available for HRG-b1-induced heterodimerization. This will again decrease the level of ErbB3 phosphorylation. HRG-b1 will, on the other hand, still induce some EGFRErbB3 heterodimerization, and if EGFR-ErbB3 internalization is inhibited compared with EGFR-EGFR internalization, EGF bound to EGFR-ErbB3 heterodimers will be endocytosed less efficiently.
It has been demonstrated that ErbB3, in contrast to EGFR and ErbB2, displays a granular cytoplasmic distribution in various human tissues (61, 62) . In line with this, we observed that ErbB3, but not EGFR, localized to endosomes in the absence of added ligand. We also found that ErbB3 was internalized from the plasma membrane in the absence of added ligand and that internalized ErbB3 partly colocalized with EEA1 in PAE cells, HeLa cells and SK-BR-3 cells. Our data additionally demonstrated that downregulation of ErbB3 from the plasma membrane to a large extent depended on clathrin. It is, however, unclear by which mechanism ErbB3 is translocated into clathrin-coated pits and also which clathrin adaptor proteins can promote recruitment of ErbB3 to coated pits. It was reported that neither ErbB2, ErbB3 nor ErbB4 could associate with the a-adaptin subunit of the adaptor protein complex-2 (26, 31) . The E3 ubiquitin ligase Nrdp1 has been shown to interact with ErbB3 independently of HRG-b1 binding and to promote a steady state degradation of ErbB3 (33, 35) . One could therefore speculate that, like in case of the EGFR, ubiquitination serves as a signal for ErbB3 internalization. Flow cytometry experiments showed that while $55% of ErbB3 was lost from the cell surface within 5 h in control cells, $20% was lost also in clathrin-depleted cells. Although this downregulation could potentially be explained by inefficient knockdown of clathrin, it could also suggest alternative mechanisms of ErbB3 downregulation acting in parallel with the clathrin-dependent endocytic pathway.
As demonstrated in this study, endocytosis of ErbB3 can occur independently of other ErbB proteins as well as independently of c-Met kinase activity. We have also demonstrated that ErbB3 was efficiently degraded and that the degradation of ErbB3 was not significantly affected by EGF or HRG-b1. However, consistent with previously reported findings (32), the degradation of ErbB3 was slightly enhanced by HRG-b1 ECD. Our data argue that ErbB3 is internalized regardless of its state of phosphorylation. Although ErbB3 has an impaired kinase activity (9) (10) (11) , ErbB3 was demonstrated to have sufficient kinase activity to trans-autophosphorylate its intracellular domain (13) . Consistently, we observed HRG-b1-induced phosphorylation of ErbB3 in PAE cells expressing ErbB3 only. Furthermore, it was suggested that ErbB3 was unable to phosphorylate exogenous substrates (13) . This could potentially explain HRG-b1-induced inhibition of EGFR downregulation if phosphorylation of adaptor/ effector proteins involved in endocytosis was reduced. Additionally, we observed a constitutive basal ErbB3 phosphorylation in cells expressing ErbB3 only. This is in line with data suggesting that overexpression of ErbB3 alone results in weak ErbB3 phosphorylation (12, 53) . The low constitutive phosphorylation of ErbB3 can possibly be explained by the recent finding that the carboxyl tail of ErbB3, in contrast to the tail of EGFR, cannot interface with the kinase domain and thus lacks autoinhibitory activity (12) . The finding that HRG-b1-induced ErbB3 phosphorylation in PAE.ErbB3 cells was blocked by the kinase inhibitor AG1478 supports the notion that ErbB3 has some constitutive kinase activity, even though AG1478 has until now been thought of as EGFR specific. The constitutive as well as the HRG-b1-induced and c-Met-independent ErbB3 phosphorylation in PAE.ErbB3 cells could further suggest that contrary to previously reported results (14) , ErbB3 may form active homodimers. 
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In summary, our results show that ErbB3 is endocytosed in a clathrin-dependent manner in the absence of added ligand and independent of its phosphorylation. Additionally, we observed that while ErbB3 is internalized independently of other ErbB proteins, its dimerization with EGFR negatively impacted on internalization of EGF and downregulation of EGFR from the plasma membrane. This could cause sustained EGF-induced signaling and contribute to the oncogenicity of ErbB3.
Supplementary material
Supplementary Figures S1-S6 can be found at http://carcin. oxfordjournals.org/.
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